• Something wrong with this record ?

Functional non-synonymous variants of ABCG2 and gout risk

B. Stiburkova, K. Pavelcova, J. Zavada, L. Petru, P. Simek, P. Cepek, M. Pavlikova, H. Matsuo, TR. Merriman, K. Pavelka,

. 2017 ; 56 (11) : 1982-1992.

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18016312

Grant support
NV15-26693A MZ0 CEP Register

Objectives: Common dysfunctional variants of ATP binding cassette subfamily G member 2 (Junior blood group) (ABCG2), a high-capacity urate transporter gene, that result in decreased urate excretion are major causes of hyperuricemia and gout. In the present study, our objective was to determine the frequency and effect on gout of common and rare non-synonymous and other functional allelic variants in the ABCG2 gene. Methods: The main cohort recruited from the Czech Republic consisted of 145 gout patients; 115 normouricaemic controls were used for comparison. We amplified, directly sequenced and analysed 15 ABCG2 exons. The associations between genetic variants and clinical phenotype were analysed using the t-test, Fisher's exact test and a logistic and linear regression approach. Data from a New Zealand Polynesian sample set and the UK Biobank were included for the p.V12M analysis. Results: In the ABCG2 gene, 18 intronic (one dysfunctional splicing) and 11 exonic variants were detected: 9 were non-synonymous (2 common, 7 rare including 1 novel), namely p.V12M, p.Q141K, p.R147W, p.T153M, p.F373C, p.T434M, p.S476P, p.D620N and p.K360del. The p.Q141K (rs2231142) variant had a significantly higher minor allele frequency (0.23) in the gout patients compared with the European-origin population (0.09) and was significantly more common among gout patients than among normouricaemic controls (odds ratio = 3.26, P < 0.0001). Patients with non-synonymous allelic variants had an earlier onset of gout (42 vs 48 years, P = 0.0143) and a greater likelihood of a familial history of gout (41% vs 27%, odds ratio = 1.96, P = 0.053). In a meta-analysis p.V12M exerted a protective effect from gout (P < 0.0001). Conclusion: Genetic variants of ABCG2, common and rare, increased the risk of gout. Non-synonymous allelic variants of ABCG2 had a significant effect on earlier onset of gout and the presence of a familial gout history. ABCG2 should thus be considered a common and significant risk factor for gout.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016312
003      
CZ-PrNML
005      
20181011143426.0
007      
ta
008      
180515s2017 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/rheumatology/kex295 $2 doi
035    __
$a (PubMed)28968913
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Stiburkova, Blanka $u Institute of Rheumatology. Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University, General University Hospital in Prague.
245    10
$a Functional non-synonymous variants of ABCG2 and gout risk / $c B. Stiburkova, K. Pavelcova, J. Zavada, L. Petru, P. Simek, P. Cepek, M. Pavlikova, H. Matsuo, TR. Merriman, K. Pavelka,
520    9_
$a Objectives: Common dysfunctional variants of ATP binding cassette subfamily G member 2 (Junior blood group) (ABCG2), a high-capacity urate transporter gene, that result in decreased urate excretion are major causes of hyperuricemia and gout. In the present study, our objective was to determine the frequency and effect on gout of common and rare non-synonymous and other functional allelic variants in the ABCG2 gene. Methods: The main cohort recruited from the Czech Republic consisted of 145 gout patients; 115 normouricaemic controls were used for comparison. We amplified, directly sequenced and analysed 15 ABCG2 exons. The associations between genetic variants and clinical phenotype were analysed using the t-test, Fisher's exact test and a logistic and linear regression approach. Data from a New Zealand Polynesian sample set and the UK Biobank were included for the p.V12M analysis. Results: In the ABCG2 gene, 18 intronic (one dysfunctional splicing) and 11 exonic variants were detected: 9 were non-synonymous (2 common, 7 rare including 1 novel), namely p.V12M, p.Q141K, p.R147W, p.T153M, p.F373C, p.T434M, p.S476P, p.D620N and p.K360del. The p.Q141K (rs2231142) variant had a significantly higher minor allele frequency (0.23) in the gout patients compared with the European-origin population (0.09) and was significantly more common among gout patients than among normouricaemic controls (odds ratio = 3.26, P < 0.0001). Patients with non-synonymous allelic variants had an earlier onset of gout (42 vs 48 years, P = 0.0143) and a greater likelihood of a familial history of gout (41% vs 27%, odds ratio = 1.96, P = 0.053). In a meta-analysis p.V12M exerted a protective effect from gout (P < 0.0001). Conclusion: Genetic variants of ABCG2, common and rare, increased the risk of gout. Non-synonymous allelic variants of ABCG2 had a significant effect on earlier onset of gout and the presence of a familial gout history. ABCG2 should thus be considered a common and significant risk factor for gout.
650    _2
$a ABC transportér z rodiny G, člen 2 $x genetika $7 D000070997
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a alely $7 D000483
650    _2
$a Česká republika $7 D018153
650    _2
$a běloši $x genetika $7 D044465
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a genetická variace $7 D014644
650    _2
$a dna (nemoc) $x genetika $7 D006073
650    _2
$a lidé $7 D006801
650    _2
$a hyperurikemie $x genetika $7 D033461
650    _2
$a lineární modely $7 D016014
650    _2
$a logistické modely $7 D016015
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x genetika $7 D009363
650    _2
$a Nový Zéland $7 D009520
650    _2
$a původní obyvatelé Havajských a ostatních tichomořských ostrovů $x genetika $7 D044468
650    _2
$a Spojené království $7 D006113
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pavelcova, Katerina $u Institute of Rheumatology. Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Zavada, Jakub $u Institute of Rheumatology.
700    1_
$a Petrů, Lenka $u Institute of Rheumatology. Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. $7 xx0228031
700    1_
$a Simek, Pavel $u Institute of Rheumatology.
700    1_
$a Cepek, Pavel $u Institute of Rheumatology.
700    1_
$a Pavlikova, Marketa $u Institute of Rheumatology.
700    1_
$a Matsuo, Hirotaka $u National Defense Medical College, Saitama, Japan.
700    1_
$a Merriman, Tony R $u Department of Biochemistry, University of Otago, Dunedin, New Zealand.
700    1_
$a Pavelka, Karel $u Institute of Rheumatology.
773    0_
$w MED00011379 $t Rheumatology (Oxford, England) $x 1462-0332 $g Roč. 56, č. 11 (2017), s. 1982-1992
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28968913 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20181011143917 $b ABA008
999    __
$a ok $b bmc $g 1299936 $s 1013152
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 56 $c 11 $d 1982-1992 $i 1462-0332 $m Rheumatology $n Rheumatology (Oxford) $x MED00011379
GRA    __
$a NV15-26693A $p MZ0
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options